{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:40:58Z","timestamp":1759333258131},"reference-count":56,"publisher":"VM Media SP. zo.o VM Group SK","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Folia Histochem Cytobiol."],"DOI":"10.2478\/v10042-009-0035-x","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T21:07:58Z","timestamp":1256677678000},"source":"Crossref","is-referenced-by-count":29,"title":["OPG\/RANK\/RANKL signaling system and its significance in nephrology."],"prefix":"10.5603","volume":"47","author":[{"given":"Katarzyna","family":"Klejna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Naumnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Gasowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3595","published-online":{"date-parts":[[2009,12,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF02409454","article-title":"Role of osteoblasts in hormonal control of bone resorption-a hypothesis","volume":"33","author":"G Rodan","year":"1981","journal-title":"Calcif Tissue Int"},{"key":"2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00774-007-0785-5","article-title":"Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients","volume":"26","author":"K Doumouchtsis","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"B Boyce","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"4","first-page":"497","article-title":"Role of OPG\/RANKL\/RANK axis on the vasculature","volume":"23","author":"A Papadopouli","year":"2008","journal-title":"Histol Histopathol"},{"key":"5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"W Simonet","year":"1997","journal-title":"Cell"},{"key":"6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"A Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"7","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"N Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"8","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"J Emery","year":"1998","journal-title":"J Biol Chem"},{"key":"9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/jcp.21430","article-title":"Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway","volume":"216","author":"E Chamoux","year":"2008","journal-title":"J Cell Physiol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.166.3.1482","article-title":"Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function","volume":"166","author":"T Yun","year":"2001","journal-title":"J Immunol"},{"key":"11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jcp.20354","article-title":"Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor","volume":"204","author":"A Zannettino","year":"2005","journal-title":"J Cell Physiol"},{"key":"12","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells","volume":"272","author":"B Wong","year":"1997","journal-title":"J Biol Chem"},{"key":"13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"D Lacey","year":"1998","journal-title":"Cell"},{"key":"14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/14779072.4.6.801","article-title":"The osteoprotegerin\/RANK\/RANKL system: a bone key to vascular disease","volume":"4","author":"S Kiechl","year":"2006","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"15","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00018-007-7104-0","article-title":"RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases","volume":"64","author":"M Baud'huin","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"P Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"L Hofbauer","year":"2004","journal-title":"Jama"},{"key":"18","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/jc.2007-0646","article-title":"CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)\/RANK ligand\/osteoprotegerin: clinical implications","volume":"92","author":"D Vega","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1359-6101(03)00027-3","article-title":"Biology of the TRANCE axis","volume":"14","author":"M Walsh","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"20","doi-asserted-by":"crossref","first-page":"75805","DOI":"10.1155\/2007\/75805","article-title":"The immune response is involved in atherosclerotic plaque calcification: could the RANKL\/RANK\/OPG system be a marker of plaque instability?","volume":"2007","author":"F Montecucco","year":"2007","journal-title":"Clin Dev Immunol"},{"key":"21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(01)05494-0","article-title":"Osteoprotegerin: a link between osteoporosis and arterial calcification?","volume":"358","author":"L Hofbauer","year":"2001","journal-title":"Lancet"},{"key":"22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"H Min","year":"2000","journal-title":"J Exp Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1161\/hq1001.097102","article-title":"Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D","volume":"21","author":"P Price","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.107.707380","article-title":"Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-\/-) mice","volume":"117","author":"S Morony","year":"2008","journal-title":"Circulation"},{"key":"25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1210\/jc.2002-020775","article-title":"Increased osteoprotegerin serum levels in men with coronary artery disease","volume":"88","author":"M Schoppet","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"26","article-title":"Osteoprotegerin, vascular calcification and atherosclerosis","author":"A Van Campenhout","year":"2008","journal-title":"Atherosclerosis"},{"key":"27","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/hq1201.100229","article-title":"Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques","volume":"21","author":"C Dhore","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.ATV.0000204334.48195.6a","article-title":"Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization","volume":"26","author":"W Sandberg","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/CIRCULATIONAHA.106.686774","article-title":"Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease","volume":"116","author":"S Kiechl","year":"2007","journal-title":"Circulation"},{"key":"30","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/sj.ki.5000311","article-title":"Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem","volume":"69","author":"F Barreto","year":"2006","journal-title":"Kidney Int"},{"key":"31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ndt\/17.2.233","article-title":"Serum osteoprotegerin and renal osteodystrophy","volume":"17","author":"G Coen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1053\/ajkd.2002.31409","article-title":"Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients","volume":"39","author":"M Haas","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11255-006-0079-1","article-title":"Serum markers of bone turnover in dialyzed patients separated according to age","volume":"38","author":"A Grzegorzewska","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1359\/JBMR.0301226","article-title":"PTH differentially regulates expression of RANKL and OPG","volume":"19","author":"J Huang","year":"2004","journal-title":"J Bone Miner Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00198-005-0047-0","article-title":"Osteoprotegerin and bone mineral density in hemodialysis patients","volume":"17","author":"A Nakashima","year":"2006","journal-title":"Osteoporos Int"},{"key":"36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/BF03350814","article-title":"sRANKL\/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients","volume":"30","author":"K Doumouchtsis","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/ajkd.2002.31402","article-title":"Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure","volume":"39","author":"J Kazama","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1515\/CCLM.2002.177","article-title":"Increased levels of osteoprotegerin in hemodialysis patients","volume":"40","author":"I Avbersek-Luznik","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1515\/CCLM.2007.306","article-title":"Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure","volume":"45","author":"M Shaarawy","year":"2007","journal-title":"Clin Chem Lab Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/ndt\/gfh672","article-title":"Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?","volume":"20","author":"I Avbersek-Luznik","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"41","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/ndt\/gfl034","article-title":"Association between phosphate removal and markers of bone turnover in haemodialysis patients","volume":"21","author":"M Albalate","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0272-6386(03)00655-3","article-title":"The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis","volume":"42","author":"K Nitta","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"43","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/ndt\/17.10.1860","article-title":"Circulating osteoprotegerin is not removed through haemodialysis membrane","volume":"17","author":"J Kazama","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"44","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"H Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"45","doi-asserted-by":"crossref","DOI":"10.1053\/ajkd.2001.27437","article-title":"Osteoprotegerin levels before and after renal transplantation","volume":"38","author":"T Sato","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bone.2007.04.190","article-title":"Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity","volume":"41","author":"A Irie","year":"2007","journal-title":"Bone"},{"key":"47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0037-1612970","article-title":"Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin","volume":"87","author":"V Pettila","year":"2002","journal-title":"Thromb Haemost"},{"key":"48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1160\/TH06-11-0671","article-title":"Heparin induces mobilization of osteoprotegerin into the circulation","volume":"98","author":"A Vik","year":"2007","journal-title":"Thromb Haemost"},{"key":"49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.2007080854","article-title":"Mechanisms of vascular calcification in chronic kidney disease","volume":"19","author":"S Moe","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"50","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"G London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"51","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1093\/ndt\/gfn226","article-title":"The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis","volume":"23","author":"R Shroff","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"52","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/ndt\/gfh263","article-title":"Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients","volume":"19","author":"K Nitta","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"53","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1093\/ndt\/gfn242","article-title":"Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients","volume":"23","author":"G Speer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"54","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1681\/ASN.2005030260","article-title":"Plasma osteoprotegerin is associated with mortality in hemodialysis patients","volume":"17","author":"M Morena","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"55","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000060815.25798.02","article-title":"Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men","volume":"107","author":"M Schoppet","year":"2003","journal-title":"Circulation"},{"key":"56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1744-9987.2008.00583.x","article-title":"Low blood osteoprotegerin levels are a predictor to poor prognosis in Japanese patients on hemodialysis due to diabetic nephropathy","volume":"12","author":"K Yokoyama","year":"2008","journal-title":"Ther Apher Dial"}],"container-title":["Folia Histochemica et Cytobiologica"],"original-title":[],"link":[{"URL":"https:\/\/journals.viamedica.pl\/folia_histochemica_cytobiologica\/article\/viewFile\/4358\/3613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,24]],"date-time":"2019-02-24T02:37:52Z","timestamp":1550975872000},"score":1,"resource":{"primary":{"URL":"http:\/\/czasopisma.viamedica.pl\/fhc\/article\/view\/4358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,10]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,12,10]]}},"URL":"https:\/\/doi.org\/10.2478\/v10042-009-0035-x","relation":{},"ISSN":["1897-5631","0239-8508"],"issn-type":[{"value":"1897-5631","type":"electronic"},{"value":"0239-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12,10]]}}}